Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, ...

Pfizer (PFE Quick Quote PFE - Free Report) reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded ...

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

$2.5 billion invested in internal research and development projects, and Approximately $110 million invested in business development transactions. Returning capital directly to shareholders through $2 ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Pfizer (PFE Quick Quote PFE - Free Report) reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded ...

Pfizer Inc. reported positive data Monday from a sub-study of a late-stage trial of a vaccine that aims to protect immunocompromised adults at risk of developing severe respiratory syncytial ...

Pfizer Inc. (NYSE:PFE) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Pfizer Inc. (NYSE:PFE) reported positive topline results from its Phase 3 BASIS study, which evaluated HYMPAVZI™ ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...